Please login to the form below

Not currently logged in
Email:
Password:

DPP-4 inhibitors

This page shows the latest DPP-4 inhibitors news and features for those working in and with pharma, biotech and healthcare.

FDA won't add outcomes data to Januvia label

FDA won't add outcomes data to Januvia label

The US regulator has sent the pharma company a complete response letter for DPP-4 inhibitor Januvia (sitagliptin) and combination product Janumet (sitagliptin plus metformin) - along with extended release formulations - saying ... The DPP-4 inhibitors as

Latest news

  • AZ gets US approval for diabetes combo Qtern AZ gets US approval for diabetes combo Qtern

    Qtern is a fixed dose combination product based on the active ingredients in AZ's DPP-4 inhibitor Onglyza (saxagliptin) and SGLT2 inhibitor Farxiga/Forixiga (dapagliflozin). ... SGLT2 inhibitors remove glucose through the urine by blocking blood glucose

  • NICE backs freer use of SGLT2 inhibitors for diabetes NICE backs freer use of SGLT2 inhibitors for diabetes

    around £475 per year and are as cost-effective as DPP-4 inhibitors. ... Technology Evaluation, noting that SGLT2 inhibitors are now "an alternative to the separate group of drugs called DPP-4 inhibitors".

  • Merck drops once-weekly diabetes drug in US and EU Merck drops once-weekly diabetes drug in US and EU

    There are thought to be other issues with once-weekly administration of DPP-4 inhibitors. ... While they are intended to reduce the burden of taking pills by diabetics and improve compliance, patients can rarely benefit from drug-free days as those on DPP

  • FDA rejects AZ's diabetes combination FDA rejects AZ's diabetes combination

    DPP-4 inhibitors are already widely used in diabetes and SGLT2 inhibitors are fast gaining ground, despite some initial concerns about safety. . ... SGLT2 inhibitors remove glucose through the urine by blocking blood glucose re-absorption in the kidney,

  • Merck gets first OK for once-weekly DPP-4 inhibitor Merck gets first OK for once-weekly DPP-4 inhibitor

    and showed that the drug is as effective at controlling blood glucose as daily DPP-4 inhibitors. ... Not all are convinced of the benefit of this approach however, particularly as most patients taking DPP-4 inhibitors also take metformin.

More from news
Approximately 2 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2013 Pharma deals during April 2013

    standalone product and in combination with other drugs, including Januvia (Merck's blockbuster DPP-4 inhibitor) and metformin. ... SGLT2 inhibitors block the reabsorption of glucose by the kidney, increasing glucose excretion, and lowering blood glucose

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics